CALGARY (Reuters) - Canada’s oil-producing province of Alberta on Thursday forecast a budget deficit of C$5.2 billion ($3.5 ...

For the full year 2025, Solventum forecasts organic sales growth of 1.0% to 2.0% and adjusted EPS of $5.45 to $5.65. The midpoint of the EPS guidance range is slightly above the current analyst ...

For the full year 2024, Erie Indemnity reported net income of $600.3 million, or $11.48 per diluted share, up from $446.1 million, or $8.53 per diluted share, in 2023. Annual revenue increased 18.5% ...

Investing.com -- Shares of Entegris (NASDAQ: ENTG) surged by 6% in after-hours trading on Thursday following the announcement that the company will be joining the S&P MidCap 400 index. This move comes ...

The biopharmaceutical company posted adjusted earnings per share of $0.43, surpassing the analyst consensus of $0.11 by $0.32. Revenue for the quarter came in at $59.1 million, beating expectations of ...

The company posted adjusted earnings per share of $0.04 for the fourth quarter, beating the analyst estimate of -$0.01. Revenue came in at $126.7 million, surpassing the consensus forecast of $109.6 ...

Definitive Healthcare’s Q4 net loss ballooned to $84.7 million, or 136% of revenue, compared to a $13.4 million loss in the same quarter last year. The company attributed $97.1 million of the loss to ...

A mega wave of regional economic data breaks on Asian markets on Friday, with investors already bracing for a nervous end to the month as they weigh up tariff threats from Washington, further signs of ...

The satellite communications company posted a loss of $0.42 per share for Q4, significantly wider than the breakeven result analysts had forecast. Revenue came in at $61.17 million, slightly above the ...

(Reuters) - The leader of one of the largest U.S. labor unions on Thursday called on top asset managers to review Tesla ...

Investing.com -- The Securities and Exchange Commission (SEC) has declared today that it is dismissing its ongoing civil ...

Compared to the same quarter last year, Amphastar’s revenue increased 4.7% from $178.1 million. The company’s top-selling product in Q4 was BAQSIMI, which generated sales of $41.8 million.